TLTao Li

Tao Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tao Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical characteristics and prognostic factors in pediatric atypical teratoid/rhabdoid tumor: a single-center retrospective study

    by Jian Li, Tianjiao Hu, Lei Wu, Lulu He, Qiyang Shen, Jianfeng Zhou, Tao Li, Li Zhou

  • Open Access

    Case Report: Early introduction of anti-GD2 immunotherapy during induction chemotherapy in high-risk neuroblastoma: two pediatric cases

    by Tianjiao Hu, Jian Li, Lulu He, Xiaojun Zhang, Jin Xu, Tao Li, Li Zhou

    Anti-Ganglioside (GD)2 monoclonal antibodies are widely used as maintenance therapy for high-risk neuroblastoma (HR-NB). However, the potential benefit of introducing immunotherapy during induction chemotherapy remains unclear. We report two pediatric patients with newly diagnosed HR-NB who received naxitamab in combination with chemotherapy starting from the second cycle of induction. Clinical characteristics, treatment regimens, and outcomes were retrospectively reviewed. Both patients achieved complete remission (CR) per International Neuroblastoma Response Criteria at the end of induction. Treatment-related adverse events, including hypotension, pain, and rash, capillary leak syndrome, and chemotherapy-related myelosuppression, were transient and manageable with supportive care and infusion adjustments. No treatment discontinuation due to toxicity occurred. While these preliminary findings demonstrate the feasibility and tolerability of early naxitamab introduction, the limited sample size precludes definitive conclusions regarding efficacy. This report provides exploratory data to support future prospective studies on optimizing the timing of anti-GD2 immunotherapy in HR-NB.


  • Open Access

    Case Report: Intracranial growing teratoma syndrome in two children with suprasellar mixed germ cell tumors: implications for the timing of surgery

    by Qizi Wu, Jian Li, Jing Ge, Lei Wu, Tao Li, Li Zhou

    Background: Intracranial growing teratoma syndrome (iGTS) is characterized by paradoxical tumor enlargement despite normalization of tumor markers during treatment of germ cell tumors. Its recognition is critical, particularly in the suprasellar region where mass effect can lead to significant morbidity. Case presentation: We report two pediatric patients with suprasellar mixed germ cell tumors treated with alternating etoposide–cisplatin and ifosfamide–etoposide chemotherapy. In both cases, serum alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (β-HCG) levels declined markedly during treatment; however, clinical deterioration and radiologic tumor enlargement occurred. Surgical resection revealed mature teratoma in both cases, confirming classic iGTS after histopathologic review. Gross total resection was achieved in both cases, followed by completion of chemotherapy and craniospinal irradiation. At follow-up, both patients remained in remission but developed permanent hypothalamic–pituitary dysfunction. Results: These cases illustrate a clear dissociation between biochemical response and local mass enlargement, consistent with classic iGTS in both patients. Conclusion: Declining tumor markers should not be interpreted as reassurance in the presence of worsening symptoms or tumor enlargement. Early surgical intervention should be considered in selected patients to relieve mass effect and potentially reduce long-term morbidity.

  • Open Access

    Imaging and pathological features of pediatric sclerosing angiomatoid nodular transformation of the spleen: a case series and hypothesis-generating perspective on non-operative management

    by Qiyang Shen, Shiyuan Wang, Jinfeng Zuo, Xingyu Liu, Fuping He, Chunlei Zhou, Sirui Pan, Nan Xie, Tao Li, Jianfeng Zhou

    Background: Sclerosing angiomatoid nodular transformation (SANT) is a benign non-neoplastic splenic lesion, well described in adults but rarely reported in children. Its clinical and imaging features in pediatric patients remain poorly characterized, and the optimal management—surgical versus non-operative—is uncertain, especially given the risks of splenectomy in children (e.g., overwhelming post‑splenectomy infection). This case series of four pediatric patients aims to describe the imaging-pathology correlation of SANT and generate a hypothesis regarding potential non-operative management in selected cases. Case Description: Four male children (age range 36–156 months) presented with solid splenic masses and underwent partial splenectomy. All four had preoperative ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI). Postoperative pathology confirmed isolated splenic SANT in three patients; one patient had synchronous splenic SANT and a separate pancreatic calcifying fibrous tumor. Imaging features varied: the characteristic “spoke‑wheel” enhancement pattern was present in only two of four cases. MRI better delineated fibrous septa, hemosiderin deposition, and nodular boundaries than CT. All patients recovered uneventfully after surgery. Follow‑up ranged from 52 to 132 months, with no recurrence or metastasis. Conclusions: Pediatric splenic SANT should be considered in the differential diagnosis of a well-circumscribed solid splenic mass, even without the classic spoke-wheel sign. Because SANT is benign and splenectomy carries risks, a hypothesis-generating alternative is close observation after percutaneous core‑needle biopsy confirmation. However, this approach requires prospective validation; When imaging findings are atypical or malignancy cannot be excluded, surgical resection remains the definitive intervention, surgical resection remains the definitive intervention.

  • Open Access

    Congenital mesoblastic nephroma: a single-center retrospective study

    by Jian Li, Mengwen Yan, Tianjiao Hu, Lei Wu, Chunlei Zhou, Qian Zhao, Qiyang Shen, Jianfeng Zhou, Lulu He, Tao Li, et al.

    Congenital mesoblastic nephroma (CMN) is a rare renal tumor predominantly occurring in neonates and young infants, and standardized treatment guidelines remain lacking. This study aimed to summarize the clinical features, therapeutic strategies, and outcomes of CMN patients from a single institution to inform clinical practice. We retrospectively reviewed the medical records of nine children with pathologically and molecularly confirmed CMN treated at Children’s Hospital of Nanjing Medical University between 2015 and 2024. Demographic characteristics, clinical presentation, imaging findings, histological subtypes, gene fusions, treatment approaches, and follow-up data were analyzed. The median age at diagnosis was 2.5 months (range: newborn to 93 months), with a male-to-female ratio of 2:1. Most patients (90%) presented with an abdominal mass detected prenatally or incidentally. The tumor originated from the right kidney in seven cases and the left in two. Ultrasound and computed tomography (CT) commonly revealed mixed cystic-solid masses, with heterogeneous enhancement on contrast imaging. Pathological subtypes included cellular (n=5), classic (n=2), and mixed (n=2). Of seven patients undergoing fluorescence in situ hybridization (FISH), three were positive for the ETV6::NTRK3 fusion; four were negative; and two relapsed patients underwent next-generation sequencing (NGS), which identified TPM3::NTRK1 and EGFR-kinase domain duplication (EGFR-KDD), respectively. All patients underwent surgical resection with a 100% resection rate. Two relapsed patients received salvage chemotherapy [vincristine-actinomycin D-cyclophosphamide (VAC) or ifosfamide-carboplatin-etoposide (ICE)], which showed limited efficacy. One relapsed patient with TPM3::NTRK1 received larotrectinib but died two months later; another with EGFR-KDD experienced disease stabilization after afatinib plus programmed cell death protein 1 (PD-1) blockade following progression on entrectinib and anlotinib. After a median follow-up of 36 months (range: 12–115 months), the overall survival was 88.9%, and the event-free survival was 77.8%. This small single-center case series describes the clinical and molecular heterogeneity of CMN. While most patients experienced favorable outcomes following surgery, relapsed cases highlight the challenges associated with molecularly atypical disease. These observations are descriptive in nature and underscore the need for larger collaborative studies to better define prognostic factors and optimal management strategies in CMN.

  • Open Access

    Successful treatment of a 4-year-old girl with pure malignant rhabdoid tumor of the bladder: a case report

    by Jian Li, Jiajia Bao, Tianjiao Hu, Qian Zhao, Jianfeng Zhou, Li Zhou, Tao Li

    Background: Extracranial malignant rhabdoid tumors (eMRTs) are rare, highly aggressive neoplasms, predominantly arising in the kidneys, with bladder involvement being extremely uncommon. Optimal management strategies, particularly bladder-preserving approaches, are not well-established due to the rarity of these cases. Case Description: We report the case of a 4-year-old girl who presented with persistent gross hematuria. Imaging revealed a large bladder mass and histopathological examination confirmed the diagnosis of an extrarenal rhabdoid tumor with loss of SMARCB1 expression. The patient underwent a multimodal treatment approach, including bladder-preserving surgery, 12 cycles of high-dose MRTK-2020 neoadjuvant chemotherapy [comprising actinomycin D, vincristine, doxorubicin, cyclophosphamide (AVDC), ifosfamide, carboplatin, and etoposide (ICE)], followed by adjuvant radiotherapy. Remarkably, the patient achieved complete remission after two cycles of chemotherapy and remained in continuous remission with no evidence of disease at the 15-month follow-up. Conclusions: This case underscores the diagnostic challenges of malignant rhabdoid tumors (MRTs) in bladder pathologies and highlights the significance of considering such tumors in differential diagnoses. Despite the limited evidence base, bladder-preserving surgeries, when feasible, should be considered and accompanied by adjuvant therapies for optimal outcomes. This case illustrates the potential for successful treatment of pure MRTs of the bladder using a combination of surgery, chemotherapy, and radiotherapy.

  • Open Access

    Inflammatory myofibroblastic tumor of the liver after adrenal neuroblastoma surgery: a case report

    by Qiyang Shen, Xingyu Liu, Lijie Zhang, Tao Li, Jianfeng Zhou

    A boy aged 55 months was diagnosed with stage IV Neuroblastoma (NB) of the right adrenal gland 2 years ago. Preoperative chemotherapy was given and he was then treated with retroperitoneal tumor resection and lymph node dissection. After surgery, the children were transferred to the Hemato-Oncology Department for chemotherapy according to the high-risk group NB, with outpatient follow-up every 6 months. In the second postoperative year, abdominal computed tomography (CT) scan revealed a rounded hypodense area in the upper part of the right posterior lobe of the liver, with marked inhomogeneous enhancement in the venous phase after enhancement, which was surgically resected, and postoperative pathology confirmed inflammatory myofibroblastic tumor (IMT) of liver. The patient was not given any special treatment after surgery. In this study, whole transcriptome sequencing was performed on the postoperative specimen of adrenal NB and the specimen of IMT of liver. This unusual case emphasizes the need for close monitoring of second tumor development in NB survivors even in the absence of known predisposing factors.


  • Open Access

    Undifferentiated embryonal sarcoma of the liver in pediatric patients: a single-institution retrospective case series

    by Jian Li, Lulu He, Qizi Wu, Jianfeng Zhou, Li Zhou, Tao Li

    Background: Undifferentiated embryonal sarcoma of the liver (UESL) is a rare and highly aggressive malignancy predominantly affecting children and adolescents. Managing UESL is particularly intricate due to its aggressive nature and the limited array of treatment options available. This study is dedicated to elucidating the efficacy of a multimodal therapeutic strategy in the successful management of UESL. Case Description: Four pediatric patients (two males, two females; aged 6–11 years) diagnosed with UESL were treated at the Children’s Hospital of Nanjing Medical University between November 2019 and June 2023. Surgical resection with lymph node dissection achieved complete primary tumor eradication. Adjuvant chemotherapy tailored to each patient’s needs was followed by localized radiation therapy. After 9–42 months of follow-up, one patient who did not undergo immediate radiotherapy experienced a relapse. Following a second operation coupled with radiotherapy, the patient achieved complete remission, and mirroring the status of the other three patients who are now presently in remission. The overall cohort exhibited commendable tolerance to the treatment regimen, with manageable chemotherapy-related toxicities. Conclusions: This case series suggests that implementing a standardized protocol of resection, followed by adjuvant chemotherapy and radiation, can lead to favorable outcomes in pediatric patients diagnosed with UESL. Nevertheless, the need for comprehensive large-scale studies is imperative to substantiate the effectiveness of this approach.


  • Open Access

    Spontaneous tumor lysis syndrome (STLS) during biopsy for burkitt lymphoma: a case report

    by Sirui Pan, Qiyang Shen, Jianfeng Zhou, Tao Li

    Tumor lysis syndrome (TLS) is a hematologic oncological emergency characterized by metabolic and electrolyte imbalances. On breakdown of tumor cells, enormous amounts of potassium, phosphate, and nucleic acids are released into systemic circulation. TLS mainly occurs during chemotherapy. However, there are rare incidences of spontaneous tumor lysis syndrome (STLS) prior to commencement of therapy. In the case being reported, the child had just undergone a biopsy. As the incision was being closed, there was a sudden onset of high fever, arrhythmia, severe hyperkalemia, hypocalcemia, and acidosis. Following timely symptomatic treatment and continuous renal replacement therapy(CRRT), the child’s laboratory results improved, and organ function was restored to normal. The final pathological diagnosis confirmed Burkitt lymphoma. The boy is currently on maintenance chemotherapy. TLS is a potentially life-threatening complication in hematologic oncology. Several important conclusions can be drawn from this case, reminding clinicians to: (1) be fully aware of the risk factors of TLS and evaluate the level of risk; (2) pay attention to the possibility of STLS during operation, if surgical procedures are necessary and operate with minimal trauma and in the shortest time possibly; (3) take preoperative prophylaxis actively for high-risk TLS patients, including aggressive fluid management and rational use of diuretics and uric-acid-lowering drugs. In addition, this case confirms the effectiveness of CRRT for severe STLS.


  • Nur77 inhibition of β-catenin expression mediates Hepatoblastoma progression and enhances cisplatin's therapeutic effect

    by Jianfeng Zhou, Xingyu Liu, Hanjun Yin, Yong Zhou, Zhongya Xu, Kai Zhou, Tao Li, Yongjun Fang, Qiyang Shen